VY7523 Phase 1/2 Alzheimer's Disease Trial

VY7523 Voyager AD NCT06874621

Overview

VY7523 is an investigational recombinant humanized IgG4 monoclonal antibody developed by [Voyager Therapeutics](https://ir.voyagertx.com) in a Phase 1/2 clinical trial for early [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@nct06874621]. The antibody targets a novel mechanism of neurodegenerative pathology distinct from established amyloid-beta (Abeta) or tau targets["@voyager_pipeline"]. The trial enrolls approximately 52 patients in a multiple ascending dose (MAD) study design.

Voyager Therapeutics is a biotechnology company focused on developing gene therapy and antibody-based treatments for severe neurological diseases. Their platform combines adeno-associated virus (AAV) delivery technology with novel therapeutic antibodies, enabling potent CNS penetration and sustained target engagement["@brunden_2021"].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT06874621 |
| Sponsor | Voyager Therapeutics |
| Phase | Phase 1/2 |
| Status | Active, recruiting |
| Study Type | Interventional |
| Indication | Early Alzheimer's Disease |
| Enrollment | Approximately 52 participants |
| Start Date | 2024 |
| Study Design | Multiple ascending dose (MAD) |

Mechanism of Action

VY7523 Voyager AD NCT06874621

Overview

VY7523 is an investigational recombinant humanized IgG4 monoclonal antibody developed by [Voyager Therapeutics](https://ir.voyagertx.com) in a Phase 1/2 clinical trial for early [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@nct06874621]. The antibody targets a novel mechanism of neurodegenerative pathology distinct from established amyloid-beta (Abeta) or tau targets["@voyager_pipeline"]. The trial enrolls approximately 52 patients in a multiple ascending dose (MAD) study design.

Voyager Therapeutics is a biotechnology company focused on developing gene therapy and antibody-based treatments for severe neurological diseases. Their platform combines adeno-associated virus (AAV) delivery technology with novel therapeutic antibodies, enabling potent CNS penetration and sustained target engagement["@brunden_2021"].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT06874621 |
| Sponsor | Voyager Therapeutics |
| Phase | Phase 1/2 |
| Status | Active, recruiting |
| Study Type | Interventional |
| Indication | Early Alzheimer's Disease |
| Enrollment | Approximately 52 participants |
| Start Date | 2024 |
| Study Design | Multiple ascending dose (MAD) |

Mechanism of Action

VY7523 is a humanized IgG4 monoclonal antibody designed to target a specific epitope involved in neurodegenerative pathways characteristic of Alzheimer's disease. The antibody-mediated targeting approach enables selective engagement of pathological proteins or aggregates contributing to neuronal dysfunction[@logovinsky_2016].

Target Pathway

While the precise molecular target is proprietary to Voyager's development program, the antibody-based approach suggests engagement with one or more of the following pathogenic mechanisms:

• Pathological protein aggregation: Targeting misfolded or aggregated proteins that drive neuronal toxicity in AD[@hardy_2006]
• Synaptic dysfunction: Interference with mechanisms that disrupt synaptic integrity and communication between neurons[@schenk_2021]
• Neuroinflammation: Modulation of inflammatory cascades that accelerate neurodegeneration

Antibody Engineering

The IgG4 isotype of VY7523 offers specific advantages for CNS therapeutic applications:

• Reduced effector function: IgG4 antibodies exhibit diminished Fcgamma receptor binding, minimizing unintended immune effector cell activation[@long_2022]
• Improved safety profile: The reduced inflammatory potential may offer a more favorable risk-benefit ratio compared to IgG1 antibodies with high effector function
• Sustained target engagement: Humanized framework supports repeated dosing necessary for chronic neurodegeneration treatment

Voyager's AAV Delivery Platform Connection

Voyager Therapeutics has built a proprietary gene therapy platform based on AAV vector technology capable of crossing the blood-brain barrier and achieving broad CNS transduction[@brunden_2021]. While VY7523 is delivered as a traditional monoclonal antibody (not AAV-mediated gene therapy), the company's expertise in CNS antibody engineering informs the antibody design:

CNS Penetrance Optimization

Voyager's experience with AAV delivery of therapeutic proteins has informed their approach to antibody engineering for CNS targets:

• Engineering of antibody properties to enhance blood-brain barrier (BBB) penetration
• Optimization of FcRn-mediated recycling to extend half-life
• Selection of epitope regions accessible in the CNS compartment

Platform Synergy

VY7523 represents a strategic expansion of Voyager's CNS antibody capabilities, complementing their AAV-based gene therapy pipeline for neurodegenerative diseases. The antibody modality offers:

• Predictable pharmacokinetics and dosing
• Well-characterized safety profile from extensive prior antibody development
• Reversible target engagement if safety concerns arise
• Faster path to clinical proof-of-concept compared to gene therapy

Clinical Development Context

Alzheimer's Disease Antibody Landscape

VY7523 enters a rapidly evolving AD antibody therapeutics field marked by recent approvals and clinical advances[@van_dyck_2023]:

| Therapeutic | Target | Company | Status |
|-------------|--------|---------|--------|
| Lecanemab | Amyloid-beta protofibrils | Eisai/Biogen | Approved |
| Donanemab | N-terminal pyroglutamate Abeta | Eli Lilly | Approved |
| Aducanumab | Aggregated amyloid-beta | Biogen | Approved |
| Gantenerumab | Fibrillar amyloid-beta | Roche | Phase 3 |
| VY7523 | Novel mechanism | Voyager | Phase 1/2 |

Novel Target Strategy

Unlike the amyloid-targeting antibodies that have dominated AD clinical development, VY7523's novel mechanism represents a differentiated approach:

Trial Design

Multiple Ascending Dose Protocol

The Phase 1/2 study employs a standard MAD design to establish safety, tolerability, and pharmacokinetics of repeated VY7523 administration:

Phase 1 (Dose Escalation)

• Sequential cohorts of escalating doses
• 3+3 design or similar to establish maximum tolerated dose
• Safety monitoring including adverse event assessment
• Pharmacokinetic sampling at multiple time points
• Biomarker collection for target engagement

• Dose expansion cohort at selected dose level
• Additional evaluation of clinical efficacy signals
• Biomarker endpoints to assess pharmacological activity
• Cognitive and functional outcome measures

Inclusion Criteria (Expected)

• Diagnosis of early AD (mild cognitive impairment due to AD or mild AD dementia)
• Confirmed amyloid pathology via PET or CSF biomarkers[@selkoe_2019]
• MMSE score in the mild range (typically 20-26)
• Stable background medications
• No significant vascular disease or other neurological conditions

Endpoints

• Primary: Safety and tolerability (adverse events, laboratory abnormalities)
• Secondary: Pharmacokinetics (serum concentration over time)
• Exploratory: Biomarker changes (CSF, plasma), cognitive measures (ADAS-Cog14, CDR-SB)

Related Mechanisms and Pathways

Alzheimer's Disease Pathogenesis

• [Amyloid-beta Cascade](/mechanisms/amyloid-cascade)
• [Tau Hyperphosphorylation](/mechanisms/tau-pathology)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction)

Related Protein Targets

• [Amyloid-beta](/proteins/amyloid-beta) — established AD target
• [Tau Protein](/proteins/tau) — pathology driver
• [APOE](/genes/apoe) — major genetic risk factor

Related Clinical Trials

• [Lecanemab Clarity AD](/clinical-trials/lecanemab-clarity-ad) — approved anti-amyloid antibody
• [Donanemab Trailblazer-ALZ 2](/clinical-trials/donanemab-trailblazer-alz2) — approved anti-amyloid antibody
• [BAN2401 Phase 1/2](/clinical-trials/ban2401-201) — amyloid protofibril antibody
• [Gantenerumab SCarlet Roads](/clinical-trials/gsk4527226-al101-nct06079190) — fibrillar amyloid antibody

Significance for Alzheimer's Disease Research

Addressing Unmet Needs

VY7523 represents an important addition to the AD therapeutic pipeline by:

Clinical Trial Importance

Phase 1/2 trials for novel mechanism AD therapeutics are critical for:

• Validating new therapeutic targets in human subjects
• Establishing safety profiles for next-generation antibody designs
• Identifying patient subgroups most likely to respond to specific mechanisms
• Building evidence for combination therapeutic approaches

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-clinical-trials)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
• [Amyloid-beta Antibodies](/therapeutics/amyloid-beta-antibodies)
• [Voyager Therapeutics](/companies/voyager-therapeutics)

External Links

• [ClinicalTrials.gov NCT06874621](https://clinicaltrials.gov/study/NCT06874621)
• [Voyager Therapeutics Pipeline](https://ir.voyagertx.com/pipeline)

References